Aehr Test's stock plummeted 10.91% during intraday trading on Tuesday, extending its recent decline from 52-week highs as investors reacted to dilution concerns from a recent equity offering.
The sharp drop follows the company's completion of a $60 million common stock public offering, which has raised investor concerns about share dilution. This capital raise comes after the stock had previously surged on securing a $41 million AI chip testing order, leading to profit-taking as the initial bullish sentiment faded.
Additionally, the broader Semiconductor Equipment sector faced significant selling pressure, with major peers like Applied Materials, ASML Holding, and Lam Research all declining, amplifying Aehr Test's pullback. Recent Form 4 filings have also heightened concerns about potential insider selling activity.
Comments